Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 11Carcinoma, Hepatocellular 4Ovarian Neoplasms 3Neoplasm Metastasis 3Small Cell Lung Carcinoma 2Neoplasms 2Nasopharyngeal Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Stomach Diseases 1Progression Free Survival 1PD-L1 Positive Non-small Cell Lung Cancer 1Lung Neoplasms 1HR+/HER2-breast Cancer 1Gastrointestinal Neoplasms 1Fludzoparib" and Anti-angiogenic 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors 1Digestive System Neoplasms 1Differentiated Thyroid Cancer 1Carcinoma, Ovarian Epithelial 1Apatinib 1Advanced Breast Cancer 1

Interventions

apatinib 1PE regimen 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Progression Free Survival × apatinib × Clear all
NCT03100955 2017-04-04

A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer

Qingdao University

Phase 3 Unknown
120 enrolled

Progression Free Survival

Data powered by HemOnc (CC BY 4.0) Colophon âš¡